Types of Cancer We Treat

Melanoma

As one of the first skin cancer treatment programs in New York City, we have long been at the forefront of melanoma research and care. We created the ABCDE screening system—now a standard diagnostic tool—to help identify melanoma at an early stage, when treatment is most effective.

Our dermatologists, dermatopathologists, oncologic surgeons, reconstructive plastic surgeons, medical oncologists, radiation oncologists, and pathologists combine their expertise to customize a treatment plan for you.

Our melanoma surgeons specialize in removing the cancer while preserving appearance and function, and our medical oncologists provide the latest targeted treatments, including genetically engineered injectable therapies.

Find a Doctor & Schedule
Diagnosis
Surgery
Targeted Drugs & Immunotherapy
Radiation Therapy

Related News

Meet the Team That Conquered Skin Cancer at Its Most Complex
Read Story
Cancer Scientists Discuss Melanoma & Lung Cancer Research
Read Story
Oncolytic Virus Shows Early Success Against Melanoma
Read Story
Dr. Janice Mehnert Works to Expand Access to Clinical Trials
Read Story
Blood Test Evaluates Effectiveness of Skin Cancer Treatment
Read Story
Perlmutter Cancer Center Expands Clinical Trials Portfolio
Read Story
Algorithm Predicts Patient Response to Skin Cancer Treatment
Read Story
NYU Langone Melanoma Surgeon Advances Treatments
Read Story
Melanoma Skin Cancer Is Killing Fewest Americans in Decades
Read Story
Melanoma Program Co-Director Searches for New Treatments
Read Story
Circular RNA Limits Skin Cancer Spread
Read Story
NYU Langone Receives Grant for Melanoma Research
Read Story

Clinical Trials and Research Studies

Phase 1

A Phase I Study of Talimogene Laherparepvec and Panitumumab in Patients with Locally Advanced Squamous Cell Carcinoma of the Skin (SCCS)

Learn More

Phase 3

A Phase 3 Randomized Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Learn More

Phase 5

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL

Learn More

Phase 5

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A

Learn More
View All Related Clinical Trials (22)